S540
Clinical – Head & neck
ESTRO 2026
awareness. These findings also have important implications for future disease prevention, prognosis, and treatment de-escalation approaches in the Israeli population. References: Lechner M, .., Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 2022 May;19(5):306-327. doi: 10.1038/s41571-022- 00603-7. Epub 2022 Feb 1. PMID: 35105976; PMCID: PMC8805140.Louredo BVR, Prado-Ribeiro AC,.., Santos-Silva AR. State-of-the-science concepts of HPV- related oropharyngeal squamous cell carcinoma: a comprehensive review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022 Aug;134(2):190-205. doi: 10.1016/j.oooo.2022.03.016. Epub 2022 Apr 8. PMID: 35725962.Amit M, Ilana K,.., Gil Z. Trends in human papillomavirus-related oropharyngeal cancer in Israel.
Digital Poster 470 Trends in HPV-Positive Oropharyngeal SCC in North Israel Over the Last Two Decades Sivan Biterman-Fisher 1,2 , Salem Billan 3,2 , Saeed Salman 3,2 , Ilana Doweck 1,2 1 Department of Otolaryngology, Carmel Medical Center, Haifa, Israel. 2 Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. 3 Oncology, Rambam Health Care Center, Haifa, Israel Purpose/Objective: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has been rising worldwide; however, national data from Israel are limited. This study aimed to evaluate temporal trends in OPSCC and HPV-related OPSCC in northern Israel. Material/Methods: A retrospective cohort analysis was conducted of patients diagnosed with OPSCC at a single tertiary referral center between 2012 and 2024. Clinical data included demographics, tumor subsite, p16 immunohistochemistry (IHC) status as a surrogate for HPV, staging, treatment modality, and outcomes. Tumors were staged according to the AJCC 8th edition. Results: A total of 160 patients (135 males, 25 females) were identified. The mean age at diagnosis was 62.5 ± 10 years, with a mean follow-up of 35.2 ± 18 months. The tonsil was the most frequent primary subsite (76 patients, 51%). HPV status was available for 133 patients, of whom 96 (72%) were p16 positive. The proportion of HPV-positive OPSCC cases increased steadily over time, from 63% during 2012–2016 to 78% during 2021–2024. In the most recent years (2023– 2024), 91–92% of OPSCC cases were HPV positive.HPV- positive and HPV-negative patients were similar in age, but the former were significantly more likely to present with tonsillar primaries (62% vs. 35%, p = 0.0028). Five-year overall survival was markedly superior among HPV-positive patients compared with HPV-negative counterparts (75% vs. 47%, p = 0.0004). Conclusion: This study provides the first longitudinal assessment of HPV-related OPSCC trends in Israel and demonstrates a marked rise in HPV-associated disease over the past decade. The overall rate of p16 positivity reached 72%, increasing to 78% in the most recent four-year period. Notably, 91–92% of OPSCC cases in 2023–2024 were HPV positive, suggesting that Israel is now approaching or possibly exceeding the prevalence levels observed in North America and Northern Europe. The results highlight a dramatic epidemiologic shift in the etiology of oropharyngeal cancer in Israel and underscore the need for public health strategies addressing HPV vaccination and
Head Neck. 2016 Apr;38 Suppl 1:E274-8. doi: 10.1002/hed.23985. Epub 2015 Jun 24. PMID: 25545260. Keywords: epidemiology, oropharynx, HPV
Digital Poster 475
The Shifting Landscape of Oropharyngeal Cancer: Epidemiological Rise of HPV and Its Impact on Survival by Stratified Risk María C. Matienzo Barreto, Elena García Morales, José J. Martín Ortega, Claudio Fuentes Sánchez Radiation Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain Purpose/Objective: The rising incidence of Human Papillomavirus-positive (HPV+) Oropharyngeal Carcinoma (OPC) has altered the disease's natural history, necessitating a refined prognostic stratification. While HPV+ status suggests a favourable outcome, the concurrent influence of traditional risk factors, such as tobacco use, may modulate this benefit. The objective of this study was to evaluate the evolving prevalence of HPV-associated OPC and to quantify the differences in treatment response, disease recurrence, and overall survival across distinct risk factor strata. Material/Methods: A retrospective, observational analysis included 83 patients with OPC who received treatment at a Level 3 Hospital between 2019 and 2022. Treatment consisted of concurrent chemoradiotherapy (75.9%) or radiotherapy alone (24.1%). Patients were stratified based on smoking status. Non-smokers were defined as having HPV infection as the sole aetiological risk factor. Results: The cohort’s median age was 60 years (range 34–85),
Made with FlippingBook - Share PDF online